Boston Scientific’s $15 billion bid for Penumbra signals major expansion in vascular treatment

Boston Scientific’s surprise bid for Penumbra marks the largest deal the Marlborough-based device maker has announced since the bruising Guidant episode two decades ago, and reflects a deliberate push by chief executive Mike Mahoney to bulk up the company’s vascular portfolio.

According to The Boston Globe, Mahoney on Thursday unveiled a roughly $15 billion cash-and-stock agreement to acquire Penumbra, the California maker of vascular devices. The company said in a statement that the combination will expand its cardiovascular and neurovascular offerings and accelerate access to therapies for patients with stroke and other vascular conditions. The acquisition follows more than 40 transactions overseen by Mahoney during his 13-year tenure, as he has sought to revive Boston Scientific’s deal-making after stabilising its core business following his arrival from Johnson & Johnson.

“Companies have a choice,” Mahoney told investors on a conference call. “Do you get stronger when you’re strong? Or do you try to get strong when you’re weaker? This is about us getting stronger when we’re very strong.” He added that landing such a big fish would not preclude the smaller “tuck-in M&A” deals Boston Scientific has continued to pursue, while acknowledging that Penumbra is larger than previous purchases he has led, “while adding ‘our company is larger.’”

The official releases from Boston Scientific and Penumbra outline a mix of cash and stock consideration and present the deal as complementary: Penumbra’s devices would broaden Boston Scientific’s treatment set for vascular disease and acute hospital interventions. Industry data and analysts cited in coverage say the deal positions Boston Scientific more competitively in neurovascular therapies, a high-growth area following increasing demand for stroke and endovascular treatment options.

Analysts on the investor call were broadly supportive of management, though some probed valuation. The Boston Globe and reporting from financial outlets noted Boston Scientific is paying about a 19 percent premium for Penumbra’s shares. One analyst complimented the secrecy around the transaction: “I would say, if either of you don’t want to be executives anymore, you can be actors because you did an excellent job making sure nobody knew about the deal, including [at] a Penumbra dinner last night,” Robbie Marcus of JPMorgan Chase said.

Boston Scientific’s experience with Guidant , a $27 billion price tag driven by a bidding war with Johnson & Johnson that hampered deal-making for years , looms as a cautionary backdrop. Company spokespeople and Mahoney have emphasised discipline in integration and capital allocation this time, framing the purchase as strategic strengthening rather than size for its own sake.

Penumbra chief executive Adam Elsesser participated in the investor call and appeared to coordinate closely with Boston Scientific’s messaging; the companies’ press statements highlighted shared goals for patient access and innovation. The official communications from both firms emphasised expected synergies and the potential to accelerate product development, while promising continuity of care for existing customers.

Regulatory review and customary closing conditions will determine the timetable for integration. In the interim, the deal will be watched closely by competitors and investors as a barometer of consolidation in the medtech sector and of Boston Scientific’s appetite for transformational, as well as bolt-on, acquisitions.